Masters Capital Management LLC Has $11.52 Million Stock Holdings in Denali Therapeutics Inc. $DNLI

Masters Capital Management LLC trimmed its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 40.0% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 600,000 shares of the company’s stock after selling 400,000 shares during the period. Masters Capital Management LLC’s holdings in Denali Therapeutics were worth $11,520,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of DNLI. Capricorn Fund Managers Ltd acquired a new position in shares of Denali Therapeutics during the fourth quarter valued at $1,027,000. Baillie Gifford & Co. boosted its holdings in Denali Therapeutics by 6.2% in the fourth quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock valued at $203,253,000 after acquiring an additional 719,304 shares during the last quarter. B. Metzler seel. Sohn & Co. AG acquired a new stake in Denali Therapeutics in the fourth quarter worth about $1,841,000. Aberdeen Group plc increased its position in Denali Therapeutics by 82.6% in the fourth quarter. Aberdeen Group plc now owns 2,032,967 shares of the company’s stock worth $33,564,000 after purchasing an additional 919,381 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Denali Therapeutics by 291.6% during the 4th quarter. SG Americas Securities LLC now owns 149,592 shares of the company’s stock worth $2,470,000 after purchasing an additional 111,391 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on DNLI. Wedbush restated an “outperform” rating and set a $26.00 target price on shares of Denali Therapeutics in a research report on Monday, July 13th. Leerink Partners lowered their price target on shares of Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. Stifel Nicolaus set a $41.00 price target on shares of Denali Therapeutics in a research note on Monday, June 22nd. JPMorgan Chase & Co. initiated coverage on shares of Denali Therapeutics in a report on Monday, July 13th. They issued an “overweight” rating and a $29.00 price objective on the stock. Finally, Wall Street Zen raised shares of Denali Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $35.17.

Denali Therapeutics Stock Performance

NASDAQ DNLI opened at $23.11 on Monday. Denali Therapeutics Inc. has a 12 month low of $12.58 and a 12 month high of $27.30. The stock has a 50-day simple moving average of $22.61 and a 200 day simple moving average of $20.86. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $3.67 billion, a PE ratio of -8.02 and a beta of 0.96.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. During the same period in the prior year, the firm posted ($0.78) EPS. Research analysts forecast that Denali Therapeutics Inc. will post -2.66 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.